We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$10B
1-Year Est. Return
135.35%
This Fund
S&P 500
This Quarter
Est. Return
-12.68%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.68B
AUM Growth
-$191M
(-10%)
Cap. Flow
+$173M
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
55%
Holding
67
New
15
Increased
26
Reduced
11
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$53.6M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$31.7M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$29.5M |
| 4 |
DMTK
DermTech, Inc. Common Stock
DMTK
|
+$28.5M |
| 5 |
PTC Therapeutics
PTCT
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$34.1M |
| 2 |
Illumina
ILMN
|
+$30.2M |
| 3 |
Arrowhead Research
ARWR
|
+$29.7M |
| 4 |
OrthoPediatrics
KIDS
|
+$14.7M |
| 5 |
Myriad Genetics
MYGN
|
+$10.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.09% |
| 2 | Communication Services | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
argenx
ARGX
$54.3B
| $3.59M | 0.21% |
31,516
+68
| +0.2% | +$9.19K |
|
52
CareDx
CDNA
$2.35B
| $3.5M | 0.21% |
154,951
+335
| +0.2% | +$9.28K |
|
|
CLSD
53
DELISTED
Clearside Biomedical
CLSD
| $2.36M | 0.14% |
+249,847
| New | +$3.58M |
|
54
Solid Biosciences
SLDB
$859M
| $1.5M | 0.09% |
9,703
+21
| +0.2% | +$2.38K |
|
55
Neuronetics
STIM
$164M
| $1.39M | 0.08% |
167,728
-546
| -0.3% | -$5.96K |
|
|
MOTS
56
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $1.34M | 0.08% |
2,252
-1,502
| -40% | -$1.22M |
|
|
OPTN
57
DELISTED
OptiNose
OPTN
| $615K | 0.04% |
5,854
+13
| +0.2% | +$1.3K |
|
|
LVGO
58
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $262K | 0.02% |
+15,000
| New | +$454K |
|
59
10x Genomics
TXG
$6.08B
| $252K | 0.02% |
+5,000
| New | +$277K |
|
|
60
Arrowhead Research
ARWR
$12.3B
| – | – |
-1,120,346
| Closed | -$29.7M |
|
|
CMMB
61
Chemomab Therapeutics
CMMB
$12.8M
| – | – |
-811
| Closed | -$233K |
|
|
62
Illumina
ILMN
$30.2B
| – | – |
-84,296
| Closed | -$30.2M |
|
|
63
OrthoPediatrics
KIDS
$573M
| – | – |
-376,647
| Closed | -$14.7M |
|
|
64
Myriad Genetics
MYGN
$301M
| – | – |
-376,586
| Closed | -$10.5M |
|
|
VRAY
65
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-159,247
| Closed | -$1.4M |
|
|
VIVE
66
DELISTED
VIVEVE MED INC
VIVE
| – | – |
-4,481
| Closed | -$1.7M |
|
Similar funds
HRCM
RA
GI
IIM
ACA
FPAS
VPIM
OIA
RTW Investments's Q3 2019 Portfolio in Review
As of Q3 2019, RTW Investments held 67 positions worth $1.68B, down 10% from $1.87B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RTW Investments deployed $173M of net new capital in Q3 2019, opening 15 new positions and adding to 26 existing holdings. Its largest new stake was Zimmer Biomet: 415,090 shares worth $55.3M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Communication Services.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $34.1M trimmed.
- RTW Investments's largest Q3 2019 buy was Zimmer Biomet: 415,090 shares worth $55.3M.
- RTW Investments added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $31.7M increase.
- RTW Investments's biggest Q3 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $34.1M.
- RTW Investments fully exited Illumina in Q3 2019, selling an estimated $30.2M.
- RTW Investments's ten largest holdings make up 55% of its $1.68B portfolio in Q3 2019.
- RTW Investments opened 15 new positions and closed 7 in Q3 2019.
- RTW Investments's portfolio value fell 10% quarter-over-quarter to $1.68B.
Based on RTW Investments's 13F filing for Q3 2019, filed 14 Nov 2019.